CAMBIUM BIO LIMITED — Director's Dealing 2020

Nov 18, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Regeneus Ltd ABN 13 127 035 358

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Leo Lee
Date of last notice	1stSeptember 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest	BNP Paribas Nominees Pty Ltd as nominee
(including registered holder)	for Yao Lee
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	13thNovember 2020

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	Direct:
	1,250,000 – options exercisable at $0.20
	per share and expiring 31 January 2024
	2,500,000 – options exercisable at $0.25
	per share and expiring 31 January 2024
	3,500,000 – options exercisable at $0.15
	per share and expiring 1 October 2024
	750,000 – options exercisable at $0.20 per
	share and expiring 1 October 2024
	750,000 – options exercisable at $0.25 per
	share and expiring 1 October 2024
	750,000 – options exercisable at $0.30 per
	share and expiring 1 October 2024
	750,000 – options exercisable at $0.35 per
	share and expiring 1 October 2024
	Indirect:
	15,890,893 fully paid ordinary shares
Class	Fully paid ordinary shares and unlisted
	options
Number acquired	N/A
Number disposed	9,000,000 unlisted options which have
	lapsed and been cancelled
Value/Consideration	Nil
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	Direct:
	1,250,000 – options exercisable at $0.20
	per share and expiring 31 January 2024
	Indirect:
	15,890,893 fully paid ordinary shares
Nature of change	Lapse and cancellation of unlisted options
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buy-
back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3